MX2022009943A - Vacunas intranasales de arnm. - Google Patents
Vacunas intranasales de arnm.Info
- Publication number
- MX2022009943A MX2022009943A MX2022009943A MX2022009943A MX2022009943A MX 2022009943 A MX2022009943 A MX 2022009943A MX 2022009943 A MX2022009943 A MX 2022009943A MX 2022009943 A MX2022009943 A MX 2022009943A MX 2022009943 A MX2022009943 A MX 2022009943A
- Authority
- MX
- Mexico
- Prior art keywords
- mrna
- intranasal
- molecules
- specifically
- antigen
- Prior art date
Links
- 108700021021 mRNA Vaccine Proteins 0.000 title abstract 2
- 229940126582 mRNA vaccine Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 108020004999 messenger RNA Proteins 0.000 abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 102100025221 CD70 antigen Human genes 0.000 abstract 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157300 | 2020-02-14 | ||
| PCT/EP2021/053633 WO2021160881A1 (en) | 2020-02-14 | 2021-02-15 | Intranasal mrna vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009943A true MX2022009943A (es) | 2022-10-18 |
Family
ID=69593570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009943A MX2022009943A (es) | 2020-02-14 | 2021-02-15 | Vacunas intranasales de arnm. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230071518A1 (https=) |
| EP (1) | EP4103226A1 (https=) |
| JP (1) | JP2023518340A (https=) |
| KR (1) | KR20230004447A (https=) |
| CN (1) | CN115443148B (https=) |
| AU (1) | AU2021219304A1 (https=) |
| BR (1) | BR112022015666A2 (https=) |
| CA (1) | CA3170239A1 (https=) |
| IL (1) | IL295507A (https=) |
| MX (1) | MX2022009943A (https=) |
| TW (1) | TW202144002A (https=) |
| WO (1) | WO2021160881A1 (https=) |
| ZA (1) | ZA202209779B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11814464B2 (en) | 2019-04-29 | 2023-11-14 | Yale University | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| AU2021293780A1 (en) | 2020-06-19 | 2023-02-02 | Yale University | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| WO2023037320A1 (en) * | 2021-09-10 | 2023-03-16 | Intron Biotechnology, Inc. | Mucosal messenger rna vaccine |
| JP2024545093A (ja) * | 2021-12-08 | 2024-12-05 | イェール ユニバーシティー | 細胞および組織に標的化するためのポリ（アミン－ｃｏ－エステル）ナノ粒子への表面コンジュゲーション |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| HUE058792T2 (hu) * | 2013-11-12 | 2022-09-28 | Univ Brussel Vrije | RNS-transzkripciós vektor és felhasználása |
| PL4023249T3 (pl) * | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| CA3040337A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| CA3088485A1 (en) * | 2018-01-18 | 2019-07-25 | Etherna Immunotherapies Nv | Lipid nanoparticles |
-
2021
- 2021-02-15 MX MX2022009943A patent/MX2022009943A/es unknown
- 2021-02-15 IL IL295507A patent/IL295507A/en unknown
- 2021-02-15 KR KR1020227031704A patent/KR20230004447A/ko active Pending
- 2021-02-15 BR BR112022015666A patent/BR112022015666A2/pt not_active IP Right Cessation
- 2021-02-15 CA CA3170239A patent/CA3170239A1/en active Pending
- 2021-02-15 WO PCT/EP2021/053633 patent/WO2021160881A1/en not_active Ceased
- 2021-02-15 JP JP2022548838A patent/JP2023518340A/ja active Pending
- 2021-02-15 EP EP21705192.9A patent/EP4103226A1/en not_active Withdrawn
- 2021-02-15 AU AU2021219304A patent/AU2021219304A1/en not_active Abandoned
- 2021-02-15 CN CN202180009112.1A patent/CN115443148B/zh not_active Expired - Fee Related
- 2021-02-15 US US17/799,118 patent/US20230071518A1/en not_active Abandoned
- 2021-02-17 TW TW110105299A patent/TW202144002A/zh unknown
-
2022
- 2022-09-01 ZA ZA2022/09779A patent/ZA202209779B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022015666A2 (pt) | 2022-09-27 |
| CA3170239A1 (en) | 2021-08-19 |
| AU2021219304A1 (en) | 2022-10-06 |
| CN115443148B (zh) | 2024-08-06 |
| WO2021160881A9 (en) | 2022-11-10 |
| TW202144002A (zh) | 2021-12-01 |
| US20230071518A1 (en) | 2023-03-09 |
| WO2021160881A1 (en) | 2021-08-19 |
| IL295507A (en) | 2022-10-01 |
| EP4103226A1 (en) | 2022-12-21 |
| ZA202209779B (en) | 2024-01-31 |
| JP2023518340A (ja) | 2023-05-01 |
| KR20230004447A (ko) | 2023-01-06 |
| CN115443148A (zh) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009943A (es) | Vacunas intranasales de arnm. | |
| Krammer et al. | Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies | |
| Krammer et al. | H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge | |
| Martinez-Gil et al. | A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant | |
| Earnest et al. | Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains | |
| Kamlangdee et al. | Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene | |
| Nogales et al. | Interplay of PA-X and NS1 proteins in replication and pathogenesis of a temperature-sensitive 2009 pandemic H1N1 influenza A virus | |
| AU2021238777A8 (en) | Modified mRNAs for vaccine development | |
| Nchioua et al. | SARS-CoV-2 variants of concern hijack IFITM2 for efficient replication in human lung cells | |
| Song et al. | Repeated low-dose influenza virus infection causes severe disease in mice: a model for vaccine evaluation | |
| WO2021202734A3 (en) | Universal influenza vaccine using nucleoside-modifield mrna | |
| CY1117896T1 (el) | Εμβολιο πρωτεϊνης συντηξης | |
| AR080111A1 (es) | Metodos y composiciones de inmunizacion | |
| Kim et al. | Complement C3 plays a key role in inducing humoral and cellular immune responses to influenza virus strain-specific hemagglutinin-based or cross-protective M2 extracellular domain-based vaccination | |
| PH12021552176A1 (en) | Antibodies and methods for treatment of influenza a infection | |
| MX2025000397A (es) | Arn autoamplificador que codifica un antigeno del virus de la gripe | |
| Hodgins et al. | A single intramuscular dose of a plant-made virus-like particle vaccine elicits a balanced humoral and cellular response and protects young and aged mice from influenza H1N1 virus challenge despite a modest/absent humoral response | |
| WO2020157222A8 (en) | Inactivated apxia, apxiia and apxiiia toxins | |
| WO2023064612A3 (en) | Pharmaceutical compositions for delivery of viral antigens and related methods | |
| Zhang et al. | Broadly protective CD8+ T cell immunity to highly conserved epitopes elicited by heat shock protein gp96-adjuvanted influenza monovalent split vaccine | |
| MX2024014492A (es) | Composiciones de arn para la administracion de antigenos de viruela simica y metodos relacionados | |
| BR112019012158A2 (pt) | vacinação eficaz contra cepas europeias de vírus da síndrome reprodutiva e respiratória suína (prrs) antes do desmame | |
| Chen et al. | Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets | |
| AU2017261305A8 (en) | DNA monoclonal antibodies targeting influenza virus | |
| Jang et al. | Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge |